{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T22:32:05Z","timestamp":1785537125063,"version":"3.56.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lipidjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.jacl.2017.01.006","type":"journal-article","created":{"date-parts":[[2017,1,18]],"date-time":"2017-01-18T13:32:54Z","timestamp":1484746374000},"page":"24-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Statin-associated muscle symptoms\u2014Managing the highly intolerant"],"prefix":"10.1016","volume":"11","author":[{"given":"James M.","family":"Backes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janelle F.","family":"Ruisinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl A.","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Moriarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2017.01.006_bib1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.atherosclerosis.2015.12.015","article-title":"Identification and management of patients with statin-associated symptoms in clinical practice: a clinician survey","volume":"245","author":"Hovingh","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2017.01.006_bib2","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jacl.2014.03.004","article-title":"An assessment by the Statin Muscle Safety Task Force: 2014 update","volume":"8","author":"Rosenson","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2017.01.006_bib3","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jacl.2012.03.003","article-title":"Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users","volume":"6","author":"Cohen","year":"2012","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2017.01.006_bib4","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1093\/eurheartj\/eht295","article-title":"Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences","volume":"34","author":"Chowdhury","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2017.01.006_bib5","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/j.cjca.2016.01.003","article-title":"Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Consensus Working Group Update (2016)","volume":"32","author":"Mancini","year":"2016","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jacl.2017.01.006_bib6","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2017.01.006_bib7","doi-asserted-by":"crossref","first-page":"526","DOI":"10.7326\/0003-4819-158-7-201304020-00004","article-title":"Discontinuation of statins in routine care settings: a cohort study","volume":"158","author":"Zhang","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacl.2017.01.006_bib8","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1345\/aph.1K604","article-title":"Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance","volume":"42","author":"Backes","year":"2008","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jacl.2017.01.006_bib9","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.amjcard.2008.09.095","article-title":"Once-a-week rosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance","volume":"103","author":"Ruisinger","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2017.01.006_bib10","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.amjcard.2008.06.050","article-title":"Effectiveness of thrice weekly ezetimibe","volume":"102","author":"Venero","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2017.01.006_bib11","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","article-title":"Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial","volume":"9","author":"Moriarty","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2017.01.006_bib12","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2016.3608","article-title":"Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial","volume":"315","author":"Nissen","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2017.01.006_bib13","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/CIRCULATIONAHA.112.136101","article-title":"Effect of statins on skeletal muscle function","volume":"127","author":"Parker","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2017.01.006_bib14","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1093\/eurheartj\/eht088","article-title":"New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs","volume":"34","author":"Norata","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2017.01.006_bib15","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2017.01.006_bib16","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2017.01.006_bib17","first-page":"383","article-title":"The effect of drug information leaflets on patient behavior","volume":"9","author":"Vinker","year":"2007","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.jacl.2017.01.006_bib18","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/eurheartj\/ehv641","article-title":"Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study","volume":"37","author":"Nielsen","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2017.01.006_bib19","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.jacl.2016.05.002","article-title":"The nocebo effect in the context of statin intolerance","volume":"10","author":"Tobert","year":"2016","journal-title":"J Clin Lipidol"},{"issue":"Suppl 2","key":"10.1016\/j.jacl.2017.01.006_bib20","doi-asserted-by":"crossref","first-page":"S243","DOI":"10.1093\/geront\/gnw002","article-title":"Musculoskeletal health conditions represent a global threat to healthy aging: a report for the 2015 World Health Organization world report on ageing and health","volume":"56","author":"Briggs","year":"2016","journal-title":"Gerontologist"},{"key":"10.1016\/j.jacl.2017.01.006_bib21","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/bjsm.37.1.30","article-title":"Musculoskeletal manifestations of diabetes mellitus","volume":"37","author":"Smith","year":"2003","journal-title":"Br J Sports Med"},{"key":"10.1016\/j.jacl.2017.01.006_bib22","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0304-3959(03)00091-5","article-title":"Musculoskeletal pain in the obese: a comparison with a general population and long-term changes after conventional and surgical obesity treatment","volume":"104","author":"Peltonen","year":"2003","journal-title":"Pain"},{"key":"10.1016\/j.jacl.2017.01.006_bib23","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients\u2013the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jacl.2017.01.006_bib24","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.jacl.2014.02.010","article-title":"The National Lipid Association's Safety Task F. A clinician's guide to statin drug-drug interactions","volume":"8","author":"Kellick","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2017.01.006_bib25","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0950-3579(05)80294-8","article-title":"Drug-induced myopathies","volume":"5","author":"Le Quintrec","year":"1991","journal-title":"Baillieres Clin Rheumatol"},{"key":"10.1016\/j.jacl.2017.01.006_bib26","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jama.289.13.1681","article-title":"Statin-associated myopathy","volume":"289","author":"Thompson","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2017.01.006_bib27","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2017.01.006_bib28","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijcard.2014.10.118","article-title":"Analysis of vitamin D levels in patients with and without statin-associated myalgia - a systematic review and meta-analysis of 7 studies with 2420 patients","volume":"178","author":"Michalska-Kasiczak","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacl.2017.01.006_bib29","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.atherosclerosis.2014.11.012","article-title":"Vitamin D status modifies the association between statin use and musculoskeletal pain: a population based study","volume":"238","author":"Morioka","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2017.01.006_bib30","first-page":"339","article-title":"Statin intolerance and vitamin D supplementation","volume":"7","author":"Khayznikov","year":"2015","journal-title":"North Am J Med Sci"},{"key":"10.1016\/j.jacl.2017.01.006_bib31","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2265.2011.04321.x","article-title":"Muscle pain and serum creatine kinase are not associated with low serum 25(OH) vitamin D levels in patients receiving statins","volume":"77","author":"Kurnik","year":"2012","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.jacl.2017.01.006_bib32","first-page":"42","article-title":"Low plasma vitamin D levels and muscle-related adverse effects in statin users","volume":"16","author":"Eisen","year":"2014","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.jacl.2017.01.006_bib33","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.phrs.2015.07.008","article-title":"Statin therapy and plasma coenzyme Q10 concentrations \u2013 a systematic review and meta-analysis of placebo-controlled trials","volume":"99","author":"Banach","year":"2015","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jacl.2017.01.006_bib34","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10545-014-9749-9","article-title":"Genetic bases and clinical manifestations of coenzyme Q10 (CoQ 10) deficiency","volume":"38","author":"Desbats","year":"2015","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.jacl.2017.01.006_bib35","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.atherosclerosis.2014.12.016","article-title":"A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy","volume":"238","author":"Taylor","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2017.01.006_bib36","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1017\/S0317167100007083","article-title":"Severe proximal myopathy with remarkable recovery after vitamin D treatment","volume":"36","author":"Al-Said","year":"2009","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.jacl.2017.01.006_bib37","first-page":"435","article-title":"Reversible muscle weakness in patients with vitamin D deficiency","volume":"167","author":"Ziambaras","year":"1997","journal-title":"West J Med"},{"key":"10.1016\/j.jacl.2017.01.006_bib38","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jff.2008.09.010","article-title":"A randomized, double-blind trial on the bioavailability of two CoQ10 formulations","volume":"1","author":"Evans","year":"2009","journal-title":"J Funct Foods"},{"key":"10.1016\/j.jacl.2017.01.006_bib39","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/jamaneurol.2014.131","article-title":"A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit","volume":"71","author":"Beal","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jacl.2017.01.006_bib40","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s13318-013-0137-x","article-title":"Is pomegranate juice a potential perpetrator of clinical drug-drug interactions? Review of the in\u00a0vitro, preclinical and clinical evidence","volume":"38","author":"Srinivas","year":"2013","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.jacl.2017.01.006_bib41","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.jacl.2016.03.071","article-title":"Statins wrongly accused of causing myalgia - guilty by association","volume":"10","author":"Ruisinger","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2017.01.006_bib42","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1345\/aph.10254","article-title":"Relief of fibromyalgia symptoms following discontinuation of dietary excitotoxins","volume":"35","author":"Smith","year":"2001","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jacl.2017.01.006_bib43","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.clnu.2014.08.012","article-title":"Non coeliac gluten sensitivity - a new disease with gluten intolerance","volume":"34","author":"Czaja-Bulsa","year":"2015","journal-title":"Clin Nutr"},{"key":"10.1016\/j.jacl.2017.01.006_bib44","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1345\/aph.1R509","article-title":"Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy","volume":"47","author":"Keating","year":"2013","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jacl.2017.01.006_bib45","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jacc.2016.03.519","volume":"68","author":"Lloyd-Jones","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2017.01.006_bib46","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2017.01.006_bib47","first-page":"637","article-title":"Ezetimibe 5 and 10 mg for lowering LDL-C: potential billion-dollar savings with improved tolerability","volume":"14","author":"Baruch","year":"2008","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.jacl.2017.01.006_bib48","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0149-2918(01)80102-8","article-title":"Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies","volume":"23","author":"Bays","year":"2001","journal-title":"Clin Ther"},{"key":"10.1016\/j.jacl.2017.01.006_bib49","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2017.01.006_bib50","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jacl.2015.12.025","article-title":"Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance","volume":"10","author":"Thompson","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2017.01.006_bib51","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S0002-9149(03)00721-5","article-title":"Effectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of high-density lipoprotein cholesterol","volume":"92","author":"Bays","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2017.01.006_bib52","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jacl.2010.07.001","article-title":"Role of dietary supplements in lowering low-density lipoprotein cholesterol: a review","volume":"4","author":"Nijjar","year":"2010","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2017.01.006_bib53","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.amjcard.2005.08.056","article-title":"Effect of plant stanol tablets on low-density lipoprotein cholesterol lowering in patients on statin drugs","volume":"97","author":"Goldberg","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2017.01.006_bib54","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jacl.2014.09.002","article-title":"Effects of Xuezhikang in patients with dyslipidemia: a multicenter, randomized, placebo-controlled study","volume":"8","author":"Moriarty","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2017.01.006_bib55","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.amjcard.2008.02.056","article-title":"Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction","volume":"101","author":"Lu","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2017.01.006_bib56","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.amjcard.2009.10.045","article-title":"Lipid-lowering efficacy of red yeast rice in a population intolerant to statins","volume":"105","author":"Venero","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2017.01.006_bib57","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.amjcard.2009.08.672","article-title":"Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance","volume":"105","author":"Halbert","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2017.01.006_bib58","doi-asserted-by":"crossref","first-page":"830","DOI":"10.7326\/0003-4819-150-12-200906160-00006","article-title":"Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial","volume":"150","author":"Becker","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacl.2017.01.006_bib59","unstructured":"ConsumerLab.com. Product Review: Red Yeast Rice Supplements Review. Available at: https:\/\/www.consumerlab.com\/reviews\/Red-Yeast-Rice-Supplements-Review\/Red_Yeast_Rice\/2014. Accessed July 8, 2016."},{"key":"10.1016\/j.jacl.2017.01.006_bib60","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ahj.2013.06.004","article-title":"Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience","volume":"166","author":"Mampuya","year":"2013","journal-title":"Am Heart J"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287417300119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287417300119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T21:23:57Z","timestamp":1536096237000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287417300119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S1933287417300119"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2017.01.006","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Statin-associated muscle symptoms\u2014Managing the highly intolerant","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2017.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 National Lipid Association. All rights reserved.","name":"copyright","label":"Copyright"}]}}